Home/Filings/4/0000950170-24-052877
4//SEC Filing

ATAI Life Sciences AG 4

Accession 0000950170-24-052877

CIK 0001098880other

Filed

May 2, 8:00 PM ET

Accepted

May 3, 4:05 PM ET

Size

8.2 KB

Accession

0000950170-24-052877

Insider Transaction Report

Form 4
Period: 2024-04-19
Transactions
  • Other

    Convertible Notes

    2024-04-19(indirect: By ATAI Life Sciences AG)
    Exercise: $0.18From: 2024-04-19Exp: 2026-02-01Common Stock (5,405,405 underlying)
Transactions
  • Other

    Convertible Notes

    2024-04-19(indirect: By ATAI Life Sciences AG)
    Exercise: $0.18From: 2024-04-19Exp: 2026-02-01Common Stock (5,405,405 underlying)
Footnotes (2)
  • [F1]On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable.
  • [F2]Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein.

Documents

1 file

Issuer

IntelGenx Technologies Corp.

CIK 0001098880

Entity typeother
IncorporatedGermany

Related Parties

1
  • filerCIK 0001776242

Filing Metadata

Form type
4
Filed
May 2, 8:00 PM ET
Accepted
May 3, 4:05 PM ET
Size
8.2 KB